Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
"MedImmune is dedicated to advancing research on the prevention and treatment of infectious diseases that put children at risk," said Edward M. Connor, M.D., executive vice president and chief medical officer. "We are committed to improving children's health both with our currently marketed products and through the potential of our robust infectious disease pipeline."
During the PAS meeting, which occurs from May 5 to 8, 2007 in Toronto, Canada, MedImmune will award several pediatric research grants through the company's annual pediatric fellowship program, which is designed to stimulate increased interest and research in the area of respiratory pathogens. Over the last 3 years, MedImmune has awarded pediatric research grants totaling nearly $700,000. In addition, MedImmune currently supports two other research grants through the Pediatric Infectious Disease Society, which will also be awarded in conjunction with the PAS annual meeting.
Data pertaining to MedImmune infectious disease programs that will be presented during the meeting include:
Influenza -- School-Based Influenza Vaccination of Elementary Students Reduced Countywide School Absenteeism (Platform Presentation) -- M. Davis et al, Saturday, May 5, 2007 from 4:45 p.m.-5:00 p.m. Eastern Time (ET), Metro Toronto Convention Centre, Room 206F -- Economic and Social Benefits of a School-Based Influenza Immunization Program (Poster Presentation) -- S. Li et al, Sunday, May 6, 2007 from 11:00 a.m. to 3:00 p.m. ET, Metro Toronto Convention Centre, Exhibit Hall E -- Post Marketing Evaluation of the Safety of LAIV (Poster Presentation)- R. Baxter et al, Sunday, May 6, 2007 from 11:00 a.m. to 3:00 p.m. ET, Metro Toronto Convention Centre, Exhibit Hall E -- Cost-Effectiveness of Cold-Adapted Influenza Vaccine, Trivalent (CAIV- T) in Preventing Influenza in Young Children Attending Daycare Centers (Poster Presentation) -- K. McLaurin et al, Tuesday, May 8, 2007 from 10:00 a.m. to 2:00 p.m. ET, Metro Toronto Convention Centre, Exhibit Hall E -- Prevention of the Influenza B Outbreak During the 2005-06 Influenza Season Through a Universal Vaccination Program in Children (Platform Presentation) -- P. Piedra et al, Tuesday, May 8, 2007 from 2:00 p.m.- 2:15 p.m. ET, Metro Toronto Convention Centre, Room 701B RSV -- Phase 3 Trial of Motavizumab, an Enhanced Potency RSV Specific Mab for the Prevention of Serious RSV Disease in High-Risk Infants (Poster Presentation) -- X. Carbonell et al, Tuesday, May 8, 2007 from 10:15 a.m. to 12:15 p.m. ET, Metro Toronto Convention Centre, Room 801B hMPV -- Prevalence and Characteristics of Human Metapneumovirus (hMPV) Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Illnesses (LRI) (Platform Presentation) -- R. Yogev et al, Sunday, May 6, 2007 from 4:15 p.m. to 4:30 p.m. ET, Metro Toronto Convention Centre, Room 707
Additional information regarding the Pediatric Academic Societies' Annual Meeting can be found at http://www.pas-meeting.org/2007Toronto/default.htm.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.
Forward Looking Statements
This announcement contains, in addition to historical information, certain "forward-looking statements" regarding the potential prospects of and the results of clinical trials for MedImmune's infectious disease marketed and pipeline products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change current expectations and could cause actual outcomes and results to differ materially from current expectations. In addition to risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission, no assurance exists that these product candidates will receive required regulatory approval or that, even if regulatory approval is received, these product candidates will be commercially successful. MedImmune undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise except as may be required by applicable law or regulation.
Notice to Investors and Stockholders of MedImmune
This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC when such become available because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. At the time the offer is commenced, AstraZeneca will file tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement will contain important information, which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be made available for free at the U.S. Securities and Exchange Commission's web site at www.sec.gov, at AstraZeneca's website at www.astrazeneca.com or at MedImmune's website at www.medimmune.com.
SOURCE MedImmune, Inc. -0- 05/02/2007 /CONTACT: media, Karen Lancaster, +1-301-398-5864, or investors, Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc./ /Web site: http://www.medimmune.com http://www.astrazeneca.com / (MEDI) CO: MedImmune, Inc. ST: Maryland, Ontario IN: IDC HEA MTC SU: TRI SVY TDS CHI AR-MT -- NEW050 -- 0241 05/02/2007 08:15 EDT http://www.prnewswire.com
Posted: May 2007